Skip to content
Government Federal, Medical Health Aged Care


Better Access Australia 2 mins read

Better Access Australia welcomes the Coalition’s recognition that without a viable community pharmacy network, access to cheaper medicines will not be a reality for many in our community. Medicines are not cheaper if your local pharmacy is no longer there to dispense them.

“We thank the Coalition for listening to patients who are calling for the Albanese Government to delay the roll out of the 60-day dispensing measure until it has been properly scoped and consulted upon as part of the eighth community pharmacy agreement (8CPA).  Better Access Australia Chair Felicity McNeill PSM said

“We all want cheaper medicines but we need to be able to access them. Reduced opening hours, pharmacy closures, reduction in services that so many rely upon because their GPs don’t have a spare appointment – we can all wait six months for cheaper medicines if it means our primary health care provider – our local pharmacy – is still there when we need it. Ms McNeill added.

“Like the Coalition, Better Access Australia has been a been strong advocate for improving the affordability of medicines for all patients since 2020.

The Coalition lead the reform of medicine costs in Australia with their 2019 election commitment to reduce safety nets.  They did it again in 2022 and were the first party to promise a reduction on the cost of medicines for general patients in the 2022 election.

“But like the Coalition and so many other parliamentarians we have watched first-hand the increasing numbers of rushed announcements in health that have had significant consequences for both patients and the health care providers that care for them.

“Reform health care with us, don’t do it to us. 

“Right now, new patients are missing out on opiate dependence treatment because the Government didn’t consult with the community, prescribers, dispensers, suppliers and wholesalers before announcing their new measure. When we should be celebrating the rectification of four years of obfuscation, we are instead all trying to ensure access is maintained and pharmacists that care for their community can continue to afford to deliver these services at reduced rates of pay.

“60-day dispensing helps patients with their cost of living, it helps government deliver the PBS for less, but what does it mean for pharmacists?

“That’s what we need to know. 

“That’s why Better Access Australia support the senate and the parliament delaying the implementation of the 60-day dispensing measure until all in the community have been consulted on 60-day dispensing as part of the 8CPA to ensure our local pharmacies remains local and open.”

Contact details:

Media contact: Felicity McNeill | M: 0460 934 638| E:


More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.